In addition, the 100-mg cohort also saw a 62% mean reduction from baseline in NT-proBNP, a biomarker of heart failure. In participants with nonobstructive HCM, 100 mg of EDG-7500 administration ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did ...

Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, ... 100 mg dose led to a 71% mean reduction in resting LVOT gradient and 58% in provokable gradient.

Edgewise Therapeutics, Inc. is trading lower this time around since I last wrote about it. Especially, in light of today's events of both 2 safety issues of AF along with the $200 million in cash ...

Edgewise Therapeutics' hypertrophic ... treatment with one dose of 200 mg of EDG-7500 in first part of the CIRRUS-HCM phase 2 trial led to a 64% mean reduction in NT-proBNP, which is a key ...

The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward ...

Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows ... The good news is that volatility and short-sellers mean the share price will likely decline to retest for ...